I'm frequently asked by my patients about whether they should cut out dietary sugar during the course of their cancer treatment. This is a complicated and nuanced discussion. In general, the short answer is no.

The claim that "sugar feeds cancer" has migrated from oncology message boards into mainstream wellness content, supplement marketing, and the dietary anxieties of patients in active treatment.^[1] Its appeal is intuitive: PET scans light up tumors using radioactive glucose, cancer cells consume glucose at elevated rates, and the metabolic shift toward glycolysis — the Warburg effect — has been documented for nearly a century.^[2] Inferring from "tumors metabolize glucose" to "dietary sugar accelerates cancer" feels biologically plausible. But is it?

The answer is actually far more complicated than the claim implies. This article examines three ideas: what metabolic biology actually shows, what observational and randomized data say about dietary sugar and cancer outcomes, and what the major oncology nutrition guidelines (ASCO, ESPEN) actually recommend during active treatment.

The Mechanistic Premise: PET Imaging, the Warburg Effect, and What It Doesn't Mean

The Warburg effect, described by Otto Warburg in the 1920s and refined in the modern molecular oncology literature,^[2][3] refers to the observation that many tumor cells preferentially use glycolysis even in the presence of adequate oxygen — for biomass synthesis and energy. This metabolic phenotype is the basis for ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG-PET), which exploits elevated glucose uptake in cancer cells to identify tumors for staging and treatment monitoring.

At a cellular level, all proliferating cells — tumor cells, activated immune cells, intestinal epithelium, hematopoietic precursors — upregulate glucose uptake to support their high metabolism. The PET signal differential between highly metabolic and normal tissues reflects the difference in glycolytic activity, not a unique tumor dependence on dietary glucose.^[3]

In the human body, blood glucose is tightly regulated. In a healthy person, fasting glucose remains between roughly 70 and 100 mg/dL regardless of dietary sugar intake; a meal containing simple sugars produces a transient postprandial excursion that returns to baseline within hours. Tumors do not "starve" when dietary sugar is reduced because the body maintains blood glucose via gluconeogenesis from other compounds like amino acids and lactate.

Observational and Trial Evidence

Restriction of postdiagnosis glucose intake has not been shown to improve cancer care outcomes by preventing recurrence nor prolonging life. Randomized trials have reported unclear or statistically insignificant differences for ketogenic diets in metastatic pancreatic cancer,^[4] local and metastatic breast cancer,^[5] and prostate cancer.^[6]

Observational studies have found that sugar intake may be associated with worsened outcomes. Specifically, sugar-sweetened beverage intake among patients with stage III colon cancer was associated with higher recurrence and mortality,^[7] and interestingly, a study found that artificially-sweetened beverage intake reduced recurrence and mortality of stage III colon cancer patients, potentially by substituting for sugar-sweetened beverages.^[8] These findings have not been consistently replicated and the residual confounding by overall dietary pattern, BMI, and physical activity is substantial.

Restriction of prediagnosis glucose intake has been associated with increased risks of developing cancer. The 2018 World Cancer Research Fund / American Institute for Cancer Research (WCRF/AICR) Continuous Update Project found probable evidence that sugar-sweetened beverage consumption increases body fatness — and strong evidence that body fatness increases risk of multiple cancers.^[9] Sugar-sweetened beverages were found to independently increase the risk of developing cancer by twofold in the population-based Nurses Health Study II^[10] and they were found to increase the risk of death by colorectal cancer and kidney cancer even after correcting for obesity in the population-based Cancer Prevention Study II.^[11]

Clinical Implications: Nutritional Adequacy During Treatment

The major oncology nutrition guidelines do not recommend limiting overall sugar intake for patients with cancer to augment their cancer treatments. The European Society for Clinical Nutrition and Metabolism (ESPEN) 2021 guideline on nutrition in cancer patients explicitly recommends against restrictive diets during active treatment, noting that cancer cachexia and treatment-induced malnutrition are far more common — and far more directly linked to worse outcomes — than excess sugar intake.^[12] The American Society of Clinical Oncology (ASCO) 2020 guideline on diet, physical activity, and weight management in cancer survivors makes similar points, recommending a generally Mediterranean dietary pattern without prescribing sugar elimination. The American Cancer Society also does not make dietary recommendations for cancer patients undergoing treatment; for general cancer prevention, it specifically recommends limiting the intake of sugar-sweetened beverages.^[13]

Patients receiving chemotherapy or radiation are often at risk of protein-energy malnutrition because they have nausea, fatigue, suppressed appetite, altered taste, and general malaise. Thus dietary restrictions can precipitate sarcopenia, delay treatment, lower quality of life, and worsen outcomes.

What the Evidence Actually Shows

The mechanistic premise — elevated glucose uptake in tumors — is real but does not translate to a clear clinical effect. All proliferating cells, including normal regenerating tissues, upregulate glucose uptake; blood glucose is homeostatically maintained by gluconeogenesis even on a low-carbohydrate diet. No randomized trial has shown that dietary sugar restriction during active treatment improves overall or progression-free survival. ESPEN and ASCO guidelines actively warn against restrictive diets during chemotherapy and radiation due to the higher-magnitude risk of treatment-induced malnutrition and cachexia.

Key Trials and Sources

1. Warner E, et al. (2022). The online cancer nutrition misinformation: a framework of behavior change based on exposure to cancer nutrition misinformation. Cancer, 128(13), 2540–2548.
2. Warburg O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314. Original description of the metabolic phenotype underlying the "sugar feeds cancer" inference. Subsequent molecular oncology has substantially refined the original interpretation.
3. Vander Heiden MG, Cantley LC, Thompson CB. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. Modern molecular reframing — cancer-cell glucose uptake reflects biosynthetic demands of proliferation, not unique dietary dependence; same phenotype is observed in normal proliferating tissues.
4. Jameson GS, et al. (2026). A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Cancer, 132(6), e70343.
5. Kodabakhshi A, et al. (2021). Effects of ketogenic metabolic therapy on patients with breast cancer: a randomized controlled clinical trial. Clinical Nutrition, 40(3), 751–758.
6. Manfrini S, et al. (2026). Ketogenic and low-carbohydrate diets in prostate cancer: metabolic rationale, preclinical evidence and preliminary clinical data. Journal of Clinical Medicine, 15(10), 3946.
7. Fuchs MA, et al. (2014). Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS ONE, 9(6), e99816. Cohort within CALGB 89803. Higher SSB intake associated with increased recurrence and mortality. Hypothesis-generating; not a randomized intervention.
8. Guercio BJ, et al. (2018). Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: results from CALGB 89803 (Alliance). PLoS ONE, 13(7), e0199244.
9. World Cancer Research Fund / American Institute for Cancer Research. (2018). Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. Continuous Update Project Expert Report. Concludes body fatness — driven partly by SSB intake — is a probable cancer risk factor; direct dietary-sugar-to-progression evidence remains limited.
10. Hur J, et al. (2021). Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. Gut, 70(12), 2330–2339.
11. McCullough ML, et al. (2022). Sugar- and artificially-sweetened beverages and cancer mortality in a large U.S. prospective cohort. Cancer Epidemiology, Biomarkers & Prevention, 31(10), 1907–1918.
12. Arends J, et al. (2021). ESPEN practical guideline: clinical nutrition in cancer. Clinical Nutrition, 40(5), 2898–2913. Recommends against restrictive diets during active treatment due to malnutrition and cachexia risk.
13. Rock CL, et al. (2022). American Cancer Society nutrition and physical activity guideline for cancer survivors. CA: A Cancer Journal for Clinicians, 72(3), 230–262. Aligned with ESPEN; recommends Mediterranean-pattern eating without specific dietary sugar targets during treatment.